The clearance brings an oral form of Novo’s Wegovy to market ahead of Lilly’s rival medication and kicks off the next phase ...
The overall leadership outlook was positive in a recent survey but varied between executives in the U.S. and those overseas.
The startup’s filing comes during a broader biotech recovery that’s made some industry watchers optimistic IPOs could rebound ...
Two pilot programs would tie Medicare costs and rebates in the U.S. to what’s paid in comparable countries. Elsewhere, AstraZeneca reported a setback and an “off the shelf” cell therapy showed promise ...
The clearance is the first in Cytokinetics’ lengthy history and pits its drug Myqorzo against Bristol Myers’ Camzyos, which ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results